Infographic: Everest II study “Which is superior? Combination therapy or monotherapy for polypoidal choroidal vasculopathy (PCV) treatment”

被引：0
|
作者：
Chinmayi Himanshuroy Vyas
Pooi Wah Lott
Rubamalar Gunatheesan
Shaun Sebastian Sim
Christopher Ziyu Sun
Kelvin Yi Chong Teo
Chui Ming Gemmy Cheung
机构：
[1] Singapore National Eye Centre,Singapore Eye Research Institute
[2] National University of Singapore,Duke
来源：
Eye | 2022年 / 36卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1140 / 1141
页数：1
相关论文
共 50 条
  • [41] EVEREST study report 3: diagnostic challenges of polypoidal choroidal vasculopathy. Lessons learnt from screening failures in the EVEREST study
    Colin S. Tan
    Wei Kiong Ngo
    Louis W. Lim
    Nikolle W. Tan
    Tock H. Lim
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254 : 1923 - 1930
  • [42] EVEREST study report 3: diagnostic challenges of polypoidal choroidal vasculopathy. Lessons learnt from screening failures in the EVEREST study
    Tan, Colin S.
    Ngo, Wei Kiong
    Lim, Louis W.
    Tan, Nikolle W.
    Lim, Tock H.
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2016, 254 (10) : 1923 - 1930
  • [43] Real world experience of the treatment outcome between photodynamic therapy combined with ranibizumab and aflibercept monotherapy in polypoidal choroidal vasculopathy
    Ma, I-Hsin
    Hsia, Yun
    Hsieh, Yi-Ting
    Ho, Tzyy-Chang
    Lai, Tso-Ting
    Yang, Chung-May
    Yang, Chang-Hao
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [44] Screening failure rates in the EVEREST II clinical trial: challenges in the diagnosis of symptomatic macular polypoidal choroidal vasculopathy
    Tan, Colin S.
    Parikh, Soumil
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [45] Real world experience of the treatment outcome between photodynamic therapy combined with ranibizumab and aflibercept monotherapy in polypoidal choroidal vasculopathy
    I-Hsin Ma
    Yun Hsia
    Yi-Ting Hsieh
    Tzyy-Chang Ho
    Tso-Ting Lai
    Chung-May Yang
    Chang-Hao Yang
    Scientific Reports, 11
  • [46] Polypoidal choroidal vasculopathy (PCV): the 4-year review of the real-life treatment experiences
    Ratanasukon, Mansing
    Bhurayanontachai, Patama
    Jirarattanasopa, Pichai
    CLINICAL OPHTHALMOLOGY, 2018, 12 : 2177 - 2181
  • [47] Comparison of visual outcomes between therapy choices and subtypes of polypoidal choroidal vasculopathy (PCV) in Taiwan: a real-world study
    Ling Yeung
    Chi-Chun Lai
    San-Ni Chen
    Cheng-Kuo Cheng
    Chung-May Yang
    Yi-Ting Hsieh
    Arslan Tsai
    Chang-Hao Yang
    Scientific Reports, 11
  • [48] ADJUSTED RETREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY AFTER COMBINATION THERAPY Results at 3 Years
    Jeon, Sohee
    Lee, Won Ki
    Kim, Kyu Seop
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2013, 33 (06): : 1193 - 1200
  • [49] Comparison of visual outcomes between therapy choices and subtypes of polypoidal choroidal vasculopathy (PCV) in Taiwan: a real-world study
    Yeung, Ling
    Lai, Chi-Chun
    Chen, San-Ni
    Cheng, Cheng-Kuo
    Yang, Chung-May
    Hsieh, Yi-Ting
    Tsai, Arslan
    Yang, Chang-Hao
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [50] Treatment of Polypoidal Choroidal Vasculopathy With Photodynamic Therapy Combined With Intravitreal Injections of Ranibizumab
    Tomita, Kaoruko
    Tsujikawa, Akitaka
    Yamashiro, Kenji
    Ooto, Sotaro
    Tamura, Hiroshi
    Otani, Atsushi
    Nakayama, Yoshihito
    Yoshimura, Nagahisa
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2012, 153 (01) : 68 - 80
12345